Description: Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Home Page: www.vaxxinity.com
VAXX Technical Analysis
1717 Main Street
Dallas,
TX
75201
United States
Phone:
254 244 5739
Officers
| Name | Title |
|---|---|
| Mr. Louis Garfield Reese IV | Co-Founder & Exec. Chairman |
| Ms. Mei Mei Hu J.D. | CEO & Director |
| Dr. Ulo Palm M.D., Ph.D. | Chief Medical Officer |
| Mr. Jason Pesile CPA, M.B.A. | Sr. VP of Fin. & Accounting |
| Mr. Dwayne Soisson | VP of Operations |
| Mr. Benjamin Matone | VP of Investor Relations |
| Mr. Rene Paula Molina | Gen. Counsel & Sec. |
| Mr. Jon Harrison | Chief Gov. Officer |
| Mr. Mark Joinnides | Chief of Staff |
| Ms. Amy B. Fix M.B.A., M.S., R.A.C. | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9213 |
| Price-to-Sales TTM: | 4604.903 |
| IPO Date: | 2021-11-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |